Call for Type 1 Diabetes Screening Gains Momentum

The approval of approval of Tzield (teplizumab) in November of 2022, the first-ever disease-modifying drug for T1D, boosted screening momentum. The BDC led clinical trials on the drug, which offers the first tangible reason for testing for the disease that halts glucose-regulating insulin production. In April, Simmons and her University of Colorado School Medicine colleagues became the first in the state to treat a clinical patient with the novel drug on the CU Anschutz Medical Campus.